Skip to main content

Table 2 Estimated time required per month to administer rituximab or trastuzumab subcutaneously or intravenously

From: Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study

Average time, min Waiting room Administration chair Medical consultation Total
IV SC IV SC IV SC IV SC
Rituximab
 Per cycle in combination with chemotherapy 71 71 296 139 20 20 387 230
 Per maintenance treatment cycle 68 53 183 21 16 15 267 89
Weighted average total time per patient per montha 86 78 302 118 23 22 411 218
Trastuzumab
 First cycle (including loading dose) in combination with chemotherapyb 83 83 187 83 17 16 286 181
 Per cycle in combination with chemotherapy (without loading dose) 85 85 162 107 17 16 264 208
 Per maintenance treatment cycle 85 60 64 15 17 16 166 91
Average total time per patient per monthb, c 127 106 163 82 26 24 316 212
  1. aThe weighted average total time per patient per month was estimated by dividing the total treatment time in a year by 12 months. Total treatment pattern in a year differs per approved indication as follows: (1) First-line follicular lymphoma (48% of patients treated with rituximab): 8 cycles in combination with chemotherapy (the first one always IV) and the last 12 as maintenance therapy; (2) Relapsed refractory follicular lymphoma (14% of patients treated with rituximab): 8 cycles in combination with chemotherapy (the first one always IV) and the last 8 as maintenance therapy; (3) Diffuse large B-cell lymphoma (38% of patients): 8 cycles in combination with chemotherapy (the first one always IV)
  2. bData for the first trastuzumab cycle (i.e. that including the loading dose) were missing from three hospitals, so the average times shown are from six of the nine hospitals
  3. cThe average total time per patient per month was estimated by first calculating the total treatment time in a year, consisting of a first cycle with loading dose in combination with chemotherapy, 7 subsequent cycles in combination with chemotherapy, and 10 cycles of maintenance therapy (giving a total of 18 cycles/year), and then dividing by 12 months
  4. IV intravenous, SC subcutaneous